VARIANTS IN MITOCHONDRIAL tRNA GENE MAY NOT BE ASSOCIATED WITH THYROID CARCINOMA
Lv F1,a, Qian G2,a, You W1,a, Lin H3, Wang XF3, Qiu GS2, Jiang YS2, Pang LX3, Kang YM4, Jia BF4, Xu JZ5,*, Yu Y1,*
*Corresponding Author: Dr. Jinzhong Xu, Department of Clinical Pharmacy, the Affiliated Wenling Hospital of Wenzhou Medial University, Taiping Nan Road 190, Wenling 317500, People’s Republic of China. Tel./Fax: +86-(0)576-8620-6288. E-mail: xujzwl@163.com and Dr. Yang Yu, Department of Breast Surgery, Henan Provincial People’s Hospital, Weiwu Road 7, Zhengzhou 450003, People’s Republic of China. Tel./Fax: +86-(0)371- 6558-0014. E-mail: 510790135@qq.com
page: 59

DISCUSSION

Mutations of mtDNA, as well as nuclear genome, are associated with various human diseases and may play important roles in age-related disorders, including cancer and aging [16]. Alterations in OXPHOS in tumor cells were originally believed to play a causative role in malignant growth and tumorigenesis [17]. On the other hand, mutations in the mt-tRNA genes have impact on the secondary and tertiary tRNA structure, and may consequently cause transcriptional and translational defects and mitochondrial respiratory chain dysfunction. More than half of mitochondrial mutations have been located in mt-tRNA genes which are hot-spots for mitochondrial pathogenesis [18]. However, we noticed that a certain amount of mt-tRNA mutations were wrongly classified as a “pathogenic” mutation, such as the C628T variant in deafness expression [9]. In this study, we evaluated seven reported mttRNA variants with thyroid cancer by employing phylogenetic conservation analysis (Table 1 and Figure 1). Of these variants, four (G7521A, T10411C, T10463C and T5655C) were located at the acceptor arm, one variant (A12308G) localized at the variable loop, one variant (G4292C) was in the anticodon loop, while the C4312T variant was at the T arm. By systematic review and literature searching, we found that only the A12308G and T5655C variants had been reported to be associated with mitochondrial diseases, while other variants were rare polymorphisms and had not been reported before. Of these, the common variant, A12308G, had been described with a wide range of clinical disorders such as stroke [19], and this variant may increase the risk of developing pigmentary retinal degeneration, short stature, dysphasia-dysarthria and cardiac conduction defects [20]. In addition, the T5655C variant had been reported to increase the penetrance and expressivity of non syndromic deafness associated with the tRNASer(UCN) T7511C mutation [21]. However, as the T5655C variant caused a slight change of ⊿G between the wild-type and the mutant tRNAAla, it indicated that it may have been served as a polymorphism. In order to examine structure-function relationships, we used the RNA Fold Web Server (http:// rna.tbi.univie. ac.at/cgi-bin/RNAfold.cgi) program to predict the optimal secondary structures for the mt-tRNAs through free energy minimization [22,23], in which the size of the minimum free energy change indicated the “driving force” behind the reaction, and the more negative the ⊿G is, the more likely was the process. We found that a wide spectrum of differences in the ⊿G of the mt-tRNAs. The largest negative differences in ⊿G (wild-type)‒⊿G(mutant)<‒3 were found in all these variants, suggesting that the polymorphic variant was energetically less favorable than the wild-type form. Previous studies showed a positive association between the known tRNALeu(CUN) A12308G variant and clinical phenotypes. However, Deschauer et al. [24] considered that this mutation may not increase the risk of stroke in patients with the tRNALeu(UUR) A3243G mutation. To address this problem, we performed a mutational analysis for the A12308G in thyroid cancer individuals and healthy controls. To our surprise, there were five patients with this variant, as well as three control subjects. This finding was consistent with a recent study by Mohammed et al. [25], and our data suggested that the A12308G variant was most probably a neutral polymorphism as it was a common event in the human genetic population. Analysis of the CIs of these variants showed that three of them exhibited high levels of conservation, including the A12308G, T10463C and T5655C (CI >70.0%). However, we noticed that not all the pathogenic mutations were conserved between different species, such as the Leber’s Hereditary Optic Neuropathy (LHON) associated ND4 G11778A mutation [26]. Most importantly, using the cybrid cells carrying these variants, by examining the steady-state level, aminoacylation ability were the “gold standards” to detect the polymorphisms and mutations [27]. Therefore, based on this study, we found that mt-tRNA variants may not be involved in the pathogenesis of thyroid carcinoma. Declaration of Interest. This study was partly supported by Zhejiang Provincial Natural Science Foundation (LQ13H280002, LY12H15001 and LY12H03001), Henan Basic and Frontier Technology Research Projects (142300410388 and 132300410048), Wenling Foundation of Science and Technology (2011WLCB0109, 2014C311051 and 2015C312055), Project of Medical Technology of Zhejiang Province (2013KYA130, 2015KYB234, 2015KYA 154, 2016KYA166 and 2016KYB275), Public Project of Science and Technology of Wenzhou City (Y20140739 and Y20150094), Ningbo Natural Science Foundation (2015A610234), and Xiangshan Science and Technology Project (2015C6005). The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.



Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006